柏林的Booster Therapeutics获得1500万美元的种子资金,用于开发新型的蛋白酶激活剂药物治疗帕金森和阿尔茨海默病. Berlin-based Booster Therapeutics receives $15M seed funding to develop novel proteasome activator medicines for Parkinson's and Alzheimer's diseases.

总部位于柏林的新生物技术公司 Booster Therapeutics 已获得 Apollo Health Ventures 和 Novo Holdings 的 1500 万美元种子资金。 Booster Therapeutics, a new biotech company based in Berlin, has launched with $15 million in seed funding from Apollo Health Ventures and Novo Holdings. 该公司旨在开发一种新型的蛋白质活性药物,以解决神经退化性疾病,特别是帕金森氏病和阿尔茨海默氏病。 The company aims to develop a novel class of proteasome activator medicines to address neurodegenerative diseases, particularly Parkinson's and Alzheimer's. 与传统方法不同,Booster的方法直接激活20S蛋白酶来降解有害蛋白质,从而创建针对各种蛋白质病变的多种疾病管道. Unlike traditional methods, Booster's approach directly activates 20S proteasomes to degrade harmful proteins, creating a multi-disease pipeline targeting various proteinopathies.